CytRx Corp

NASDAQ: CYTR
$0.38
+$0.01 (+3.0%)
Closing price April 8, 2020
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
Chris Lange
Even though the market made incredible gains this past week, a few companies held it back from pushing even higher.
Chris Lange
CytRx absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results.
Chris Lange
If the momentum in biotech can continue, then companies with catalysts within the next 12 to 18 months could get an added boost with any good news.
24/7
The top analyst calls for Thursday, January 7, 2016, include Newmont Mining, Noble Energy, Paychex, Pioneer Natural Resources, Southwest Airlines and Wells Fargo.
Jon C. Ogg
Source: ThinkstockThe stock market has remained very choppy so far in 2015. Still, the bull market is now six years old and many analysts and market pundits expect the gains to resume in the months...
Jon C. Ogg
Friday's top analyst upgrades, downgrades and initiations include Apple, CyberArk, EMC, Goldman Sachs, SanDisk, ULTA Beauty and Wayfair.
Jon C. Ogg
This past week we scoured our Wall Street coverage looking for analysts stock picks that have huge upside targets, and we were not disappointed. We found five stocks from four different firms.
Lee Jackson
Source: ThinkstockStocks are indicated lower on Monday, with the S&P 500 futures down seven points at 1,867.50 and DJIA futures down 61 points around 16,386. Investors and traders alike are still...
Jon C. Ogg
Source: Jon OggCytRx Corporation (NASDAQ: CYTR) saw its shares get punished on Friday for a secondary offering. Frankly, the pricing of the deal was such that it punished every single shareholder who...
Jon C. Ogg
24/7 Wall St. ran a screen of the Wall Street firms we cover looking for biotech stocks trading under $10 that had big upside potential for 2014. These are potentially the next great growth engines...
Lee Jackson
There are a number of reasons that insiders and large holders sell shares of public companies. There is really only one reason that insiders and large holders buy shares, and that is because they...
Jon C. Ogg
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.  The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set to take...
Jon C. Ogg
It is now getting close to the middle of May, and that means one thing for biotech investors.  The king of biotech and pharma events is about to take place.  The 2012 annual meeting of the American...
Jon C. Ogg
Today’s version of the BioHealth Business Daily is a very unusual lot of movers.  Some moves are merely in sympathy and some are on news.  We also have a re-review of Amgen Inc. (NASDAQ: AMGN)...
Jon C. Ogg